Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
5.11
+0.01 (0.10%)
Sep 3, 2026, 2:30 PM EDT - Market open
Arbutus Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 181.72 | 14.08 | 6.17 | 18.14 | 39.02 | 10.99 | |
Revenue Growth | 1078.78% | 128.21% | -65.98% | -53.51% | 255.11% | 58.92% |
Cost of Revenue | 17.8 | 25.24 | 54.04 | 73.7 | 84.41 | 65.5 |
Gross Profit | 163.92 | -11.16 | -47.87 | -55.56 | -45.39 | -54.51 |
Selling, General & Admin | 16.49 | 15.89 | 22.11 | 22.48 | 17.83 | 17.14 |
Operating Expenses | 16.49 | 15.89 | 22.11 | 22.48 | 17.83 | 17.14 |
Operating Income | 147.43 | -27.05 | -69.97 | -78.03 | -63.22 | -71.65 |
Interest Expense | -0.08 | -0.1 | -0.14 | -0.46 | -1.73 | -2.86 |
Interest & Investment Income | 3.49 | 4.07 | 6.59 | 5.69 | 2.19 | 0.13 |
Currency Exchange Gain (Loss) | -0.03 | 0.01 | -0.05 | 0.03 | -0.02 | 0.01 |
EBT Excluding Unusual Items | 150.81 | -23.07 | -63.58 | -72.78 | -62.78 | -74.38 |
Merger & Restructuring Charges | -0.4 | -12.94 | -3.72 | - | - | - |
Gain (Loss) on Sale of Assets | 0.67 | 0.67 | - | - | - | - |
Other Unusual Items | 1.97 | 1.83 | -2.63 | -0.07 | -2.23 | -1.87 |
Pretax Income | 153.05 | -33.5 | -69.92 | -72.85 | -65.01 | -76.25 |
Income Tax Expense | - | - | - | - | 4.44 | - |
Net Income | 153.05 | -33.5 | -69.92 | -72.85 | -69.46 | -76.25 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 12.14 |
Net Income to Common | 153.05 | -33.5 | -69.92 | -72.85 | -69.46 | -88.39 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 194 | 192 | 186 | 166 | 151 | 106 |
Shares Outstanding (Diluted) | 194 | 192 | 186 | 166 | 151 | 106 |
Shares Change | 2.21% | 3.23% | 11.84% | 9.95% | 42.07% | 40.10% |
EPS (Basic) | 0.79 | -0.17 | -0.38 | -0.44 | -0.46 | -0.83 |
EPS (Diluted) | 0.79 | -0.17 | -0.38 | -0.44 | -0.46 | -0.83 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -24.63 | -39.64 | -65.03 | -86.94 | -35.87 | -68.34 |
Free Cash Flow Per Share | -0.13 | -0.21 | -0.35 | -0.52 | -0.24 | -0.64 |
Gross Margin | 90.20% | -79.23% | - | - | -116.32% | - |
Operating Margin | 81.13% | -192.08% | -1133.92% | -430.15% | -162.03% | -652.07% |
Profit Margin | 84.23% | -237.88% | -1133.04% | -401.57% | -178.01% | -804.39% |
Free Cash Flow Margin | -13.55% | -281.45% | -1053.83% | -479.27% | -91.92% | -621.96% |
EBITDA | 147.47 | -26.69 | -68.59 | -76.63 | -61.8 | -69.9 |
EBITDA Margin | 81.15% | -189.50% | - | - | -158.37% | - |
D&A For EBITDA | 0.04 | 0.36 | 1.38 | 1.4 | 1.43 | 1.75 |
EBIT | 147.43 | -27.05 | -69.97 | -78.03 | -63.22 | -71.65 |
EBIT Margin | 81.13% | -192.08% | - | - | -162.03% | - |
Revenue as Reported | 181.72 | 14.08 | 6.17 | 18.14 | 39.02 | 10.99 |